Navigation Links
Advanced Therapy Aids Stroke Patients
Date:1/23/2008

clot.

In this study, the researchers compared 80 patients who received IV therapy and 43 patients who received IA therapy at Sacred Heart from 2004 through 2007. Some of the patients who received IA therapy had not responded to IV therapy.

Success rates of IA therapy (defined as opening up of the blocked blood vessel) were 85.7 percent in 2006 and 83.3 percent in 2007. Death rates among patients who received IA therapy were 30.8 percent in 2006 and 27.8 percent in 2007. That's half the 50 percent to 80 percent death rates published in the "natural history outcomes" of large-vessel strokes, the study authors said.

"Without any question, we definitely were able to help patients who failed IV therapy by providing IA therapy," Zylak said. "In the future, for large-vessel clots, IA therapy may well be the best direct therapy, bypassing IV therapy."

He noted that many stroke victims don't receive any treatment, because they don't recognize the signs (such as vision and speech problems, paralysis, and memory difficulties) and don't seek medical care. The sooner a stroke is treated, the more likely treatment will be successful.

"Overall, we are under-treating stroke. There are many patients who could benefit from stroke treatment who aren't getting it for various reasons," Zylak said. "Treatment therapies today are getting dramatic results. If a medical center doesn't offer the more advanced IA therapy, the patient can be taken by helicopter to a center that performs the therapy, even if IV therapy wasn't successful."

Stroke is the third leading cause of death in the United States, killing about 160,000 people a year, according to the National Stroke Association. About 750,000 people suffer from stroke annually.

More information

The Washington University School of Medicine has more about ischemic stroke.


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Foundation Radiology Group Formalizes Strategic Partnership with Emageon to Provide Advanced Imaging Software to Facilitate Industry-Leading Turnaround and Patient Care Response Times
2. Advanced Home Care Extends Its Use of Authentidates Inscrybe(TM) Healthcare Platform
3. Bevacizumab found to improve survival for patients with advanced breast cancer
4. Study examines factors associated with survival in advanced laryngeal cancer
5. With Calorie Counting on Holiday Hiatus, NutriSystem Offers Advanced Resolution for 2008
6. New Survey Underscores Importance of Psychosocial and Educational Needs Among Women with Advanced Breast Cancer
7. Survey underscores importance of emotional/educational needs among women with advanced breast cancer
8. Advanced Life Sciences Completes Private Placement for $20 Million
9. Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinsons Disease
10. Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma
11. Advanced Clinical Research Services Enhances Biostatistics Offering
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Advanced Therapy Aids Stroke Patients
(Date:10/22/2014)... Cheap Hosting USA is among the most distinguished review ... that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best cheap ... , “iPower is one of the most reliable hosting ... of useful products for new and old clients. What’s ... and a number of features which will appeal to ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In ... in the face, it certainly can be difficult to choose ... an extra favor by doing it the healthy way? Set ... listen to your body, exercise regularly, and choose foods with ... losing weight; you need to exercise more and eat less. ...
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... Black women undergoing in vitro fertilization (IVF) are only about ... the popular assisted reproduction technique, new research indicates, and the ... In the study, about 31 percent of white patients became ... patients. Analyzing more than 4,000 IVF cycles over two ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
... Are Ignoring the Fight Against Cancer, CLEVELAND, ... took the stage for a final debate before ... matters important to the,American public but fell short ... cancer is an issue identified by 62 percent ...
... Clinton Defends Healthcare Plan Built on Extending Customers and ... Revenue of Private Insurance ... Moore,participated in a press conference call today organized by ... from the movie SiCKO, including Reggie Cervantes, a,9/11 rescue ...
... Aflac Incorporated,(NYSE: AFL ) announced today that ... 29th Annual Institutional Investors Conference. President and Chief,Financial ... he is scheduled to make a presentation on ... Incorporated presentation, Mr. Cloninger will discuss the,company,s outlook ...
... of the worlds pre-eminent experts in urogynecology at Oregon Health ... the National Institutes of Health to study the extent of ... , The pelvic floor comprises the muscle group that ... injury, which is caused by damage to pelvic muscles or ...
... Citing a Center for,Medicare and Medicaid Services (CMS) ... 20 percent of national health care spending by,2017, ... statement,urging the House to take up legislation introduced ... (D-Md.) to safeguard Medicare:, "Looking at this ...
... -- Millions of cancer patients take drugs to boost ... anemic after chemotherapy. But a new study by Northwestern ... erythropoiesis-stimulating agents (ESAs), actually raise patients, risk of death, ... , A meta-analysis of 51 trials with 13,613 patients ...
Cached Medicine News:Health News:Democratic Candidates Miss Key Health Issue in Debate 2Health News:Michael Moore Defends 9/11 Rescue Workers and Criticizes Insurance Industry on California Nurses Association Press Call 2Health News:Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference 2Health News:NIH awards OHSU researcher $1.2 million to determine causes of, risk factors for pelvic floor injury 2Health News:Blunt Cites New CMS Report in Calling for Action on Safeguarding Medicare 2Health News:Drug for anemic cancer patients raises risk of death 2Health News:Drug for anemic cancer patients raises risk of death 3
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... 2014  Indianapolis interventional medical device maker ... -based 3D visualization leader Synaptive Medical ... Annual Meeting that they have joined forces to ... collaboration is the first of its kind and ... outcomes. NICO,s BrainPath® interventional access technology and Synaptive,s ...
(Date:10/20/2014)...   BioNano Genomics announced today achievement of a ... human data at 30X depth, sufficient for a genome map, ... was established and demonstrated for the IrysChip TM V2, ... and will be rolled out to BioNano,s collaborators and ... this advancement at the American Society for Human Genetics ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... Calif., Oct. 19 NovaBay Pharmaceuticals , ... non-antibiotic anti-infective compounds for the treatment or prevention of a ... that the company has named Mark Anderson, Ph.D. as chief ... , "We are adding Mark to our team at a ...
... Sanofi-aventis U.S. announced that the U.S. Food and ... (rasburicase) to be used for the initial management of ... leukemia, lymphoma, and solid tumor malignancies who are receiving ... (TLS) and subsequent elevations of plasma uric acid. ...
Cached Medicine Technology:NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer 2NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer 3FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy 2FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy 3FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy 4FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy 5FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy 6FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy 7
... The HeartStart FRx Defibrillator was designed ... the HeartStart OnSite Defibrillator and shares many ... intuitive icon-driven operation. The Philips HeartStart Home ... that is approved for home use by ...
... Alpha 5 is Aloka's latest advance ... operating room. Aloka's ProSound technology transmits ... information in a pure sound field., ... large-scale integration of the electronic circuit ...
... Disease ELISA kits utilize ... Also included in each ... negative controls, serum diluent, ... Use an ELISA plate ...
Test for Anti-HBc for use on the Abbott Prism...
Medicine Products: